
-
Arcutis Biotherapeutics NasdaqGS:ARQT Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Location: 3027 Townsgate Road, Westlake Village, CA, 91361, United States | Website: https://www.arcutis.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.542B
Cash
198.1M
Avg Qtr Burn
-27.73M
Short % of Float
18.67%
Insider Ownership
1.95%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ZORYVE® (Roflumilast foam 0.3%) Details Skin disease/disorder, Seborrheic dermatitis | Approved Quarterly sales | |
ZORYVE® (ARQ-151) topical roflumilast cream Details Atopic dermatitis | Approved Quarterly sales | |
ZORYVE® (ARQ-151) topical roflumilast cream Details Skin disease/disorder, Psoriasis | Approved Quarterly sales | |
ZORYVE® (ARQ-151) topical roflumilast cream Details Psoriasis, Skin disease/disorder, Chronic obstructive pulmonary disease, Pulmonary hypertension | Approved Quarterly sales | |
ZORYVE® (roflumilast) Topical Foam 0.3% Details Plaque Psoriasis | Approved Quarterly sales | |
ZORYVE® (ARQ-151) topical roflumilast cream Details Atopic dermatitis | PDUFA Approval decision | |
ARQ-255 topical ivarmacitinib Details Skin disease/disorder, Alopecia areata | Phase 1b Data readout | |
ARQ-234 Details Skin disease/disorder, Atopic dermatitis | IND Submission | |
ARQ-252 (JAKi) Details Vitiligo | Failed Discontinued | |
ARQ-252 (JAK1i) Details Skin disease/disorder, Eczema | Failed Discontinued |